Advertisement

Blue Light Endoscopy

  • Saman Moazami
  • Mark P. Schoenberg
  • Joshua M. Stern
Chapter

Abstract

The ability to accurately predict pathologic stage and grade of Upper Tract Urothelial Cell Carcinoma (UTUC) is crucial for prognostication and selection of appropriate therapeutic intervention. The advent of high definition flexible ureteroscopy has increased the use of minimally invasive endoscopic evaluation and treatment of UTUC. Nonetheless, accurate endoscopic staging of upper tract tumors remains challenged by difficult visualization and the limited size of the pathologic specimen obtained. Adjunct technology that could help accurately stage endoscopic biopsies would be of benefit to patients with UTUC. Blue light endoscopy (HAL-BLC) is such a technology, and has been recently adopted adjunct to standard white light endoscopy in bladder cancer management. Data on HAL-BLC show increasing rates of tumor detection and an increase in recurrence free survival. There are small, but promising early studies using photodynamic therapy in the upper tract which are reviewed herein.

Keywords

Upper tract urothelial cell carcinoma Blue light Ureteroscopy Photodynamic therapy 5-ALA HAL 

References

  1. 1.
    Yamany T, van Batavia J, Ahn J, Shapiro E, Gupta M. Ureterorenoscopy for upper tract urothelial carcinoma: how often are we missing lesions? Urology. 2015;85(2):311–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Audenet F, Traxer O, Yates DR, Cussenot O, Roupret M. Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract. BJU Int. 2012;109(4):608–13; discussion 13–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Guarnizo E, Pavlovich CP, Seiba M, Carlson DL, Vaughan ED Jr, Sosa RE. Ureteroscopic biopsy of upper tract urothelial carcinoma: improved diagnostic accuracy and histopathological considerations using a multi-biopsy approach. J Urol. 2000;163(1):52–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Smith AK, Stephenson AJ, Lane BR, Larson BT, Thomas AA, Gong MC, et al. Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology. 2011;78(1):82–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Bus MT, de Bruin DM, Faber DJ, Kamphuis GM, Zondervan PJ, Laguna Pes MP, et al. Optical diagnostics for upper urinary tract urothelial cancer: technology, thresholds, and clinical applications. J Endourol Endourol Soc. 2015;29(2):113–23.CrossRefGoogle Scholar
  6. 6.
    Gayed BA, Bagrodia A, Gaitonde M, Krabbe LM, Meissner M, Kapur P, et al. Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: preliminary results. Urol Oncol. 2015;33(1):18 e21–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Allison RR. Photodynamic therapy: oncologic horizons. Future Oncol. 2014;10(1):123–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Allison RR, Moghissi K. Photodynamic therapy (PDT): PDT mechanisms. Clin Endosc. 2013;46(1):24–9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ahmad S, Aboumarzouk O, Somani B, Nabi G, Kata SG. Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma—a prospective audit. BJU Int. 2012;110(11 Pt B):E596–600.CrossRefPubMedGoogle Scholar
  10. 10.
    Kloek J, Akkermans W. Beijersbergen van Henegouwen GM. Derivatives of 5-aminolevulinic acid for photodynamic therapy: enzymatic conversion into protoporphyrin. Photochem Photobiol. 1998;67(1):150–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Mroz P, Yaroslavsky A, Kharkwal GB, Hamblin MR. Cell death pathways in photodynamic therapy of cancer. Cancers. 2011;3(2):2516–39.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Marti A, Lange N, van den Bergh H, Sedmera D, Jichlinski P, Kucera P. Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach. J Urol. 1999;162(2):546–52.CrossRefPubMedGoogle Scholar
  13. 13.
    Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3(5):380–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Lipson RL, Baldes EJ, Olsen AM. Hematoporphyrin derivative: a new aid for endoscopic detection of malignant disease. J Thorac Cardiovasc Surg. 1961;42:623–9.PubMedGoogle Scholar
  15. 15.
    Kelly JF, Snell ME. Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. J Urol. 1976;115(2):150–1.CrossRefPubMedGoogle Scholar
  16. 16.
    Somani BK, Moseley H, Eljamel MS, Nabi G, Kata SG. Photodynamic diagnosis (PDD) for upper urinary tract transitional cell carcinoma (UT-TCC): evolution of a new technique. Photodiagn Photodyn Ther. 2010;7(1):39–43.CrossRefGoogle Scholar
  17. 17.
    Zaak D, Kriegmair M, Stepp H, Stepp H, Baumgartner R, Oberneder R, et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology. 2001;57(4):690–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, Grimm MO, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 2005;174(3):862–6; discussion 6.CrossRefPubMedGoogle Scholar
  19. 19.
    Lotan Y. Promises and challenges of fluorescence cystoscopy. Urologic Oncol. 2015.CrossRefPubMedGoogle Scholar
  20. 20.
    Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol. 2012;188(1):58–62.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Dragoescu O, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64(5):846–54.CrossRefPubMedGoogle Scholar
  22. 22.
    Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, et al. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014;11(10):589–96.CrossRefPubMedGoogle Scholar
  23. 23.
    Smith P, Mandel J, Raman JD. Conservative nephron-sparing treatment of upper-tract tumors. Curr Urol Rep. 2013;14(2):102–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115(6):1224–33.CrossRefPubMedGoogle Scholar
  25. 25.
    Langner C, Hutterer G, Chromecki T, Winkelmayer I, Rehak P, Zigeuner R. pT classification, grade, and vascular invasion as prognostic indicators in urothelial carcinoma of the upper urinary tract. Mod Pathol. 2006;19(2):272–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Li CC, Chang TH, Wu WJ, Ke HL, Huang SP, Tsai PC, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol. 2008;54(5):1127–34.CrossRefPubMedGoogle Scholar
  27. 27.
    Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998;52(4):594–601.CrossRefPubMedGoogle Scholar
  28. 28.
    Keeley FX, Kulp DA, Bibbo M, McCue PA, Bagley DH. Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma. J Urol. 1997;157(1):33–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Skolarikos A, Griffiths TR, Powell PH, Thomas DJ, Neal DE, Kelly JD. Cytologic analysis of ureteral washings is informative in patients with grade 2 upper tract TCC considering endoscopic treatment. Urology. 2003;61(6):1146–50.CrossRefPubMedGoogle Scholar
  30. 30.
    Furukawa J, Miyake H, Sakai I, Fujisawa M. Significance of ureteroscopic biopsy grade in patients with upper tract urothelial carcinoma. Curr Urol. 2013;6(3):156–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Lucas SM, Svatek RS, Olgin G, Arriaga Y, Kabbani W, Sagalowsky AI, et al. Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. BJU Int. 2008;102(2):172–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Roupret M, Hupertan V, Traxer O, Loison G, Chartier-Kastler E, Conort P, et al. Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology. 2006;67(6):1181–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Cutress ML, Stewart GD, Wells-Cole S, Phipps S, Thomas BG, Tolley DA. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int. 2012;110(11):1608–17.CrossRefPubMedGoogle Scholar
  34. 34.
    Waidelich R, Hofstetter A, Stepp H, Baumgartner R, Weninger E, Kriegmair M. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of upper tract urothelial tumors. J Urol. 1998;159(2):401–4.CrossRefPubMedGoogle Scholar
  35. 35.
    Aboumarzouk OM, Mains E, Moseley H, Kata SG. Diagnosis of upper urinary tract tumours: is photodynamic diagnosis assisted ureterorenoscopy required as an addition to modern imaging and ureterorenoscopy? Photodiagn Photodyn Ther. 2013;10(2):127–33.CrossRefGoogle Scholar
  36. 36.
    Kata SG, Aboumarzouk OM, Zreik A, Somani B, Ahmad S, Nabi G, et al. Photodynamic diagnostic ureterorenoscopy: a valuable tool in the detection of upper urinary tract tumour. Photodiagnosis and photodynamic therapy. Photodiagn Photodyn Ther. 2016;13:255–60. doi: 10.1016/j.pdpdt.2015.08.002 Epub 2015 Aug 6.CrossRefGoogle Scholar
  37. 37.
    Jarrett TW, Sweetser PM, Weiss GH, Smith AD. Percutaneous management of transitional cell carcinoma of the renal collecting system: 9-year experience. J Urol. 1995;154(5):1629–35.CrossRefPubMedGoogle Scholar
  38. 38.
    Keeley FX Jr, Bagley DH. Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. J Urol. 1997;158(6):2074–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Thalmann GN, Markwalder R, Walter B, Studer UE. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol. 2002;168(4 Pt 1):1381–5.CrossRefPubMedGoogle Scholar
  40. 40.
    Patel A, Fuchs GJ. New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma. J Urol. 1998;159(1):71–5.CrossRefPubMedGoogle Scholar
  41. 41.
    Nonomura N, Ono Y, Nozawa M, Fukui T, Harada Y, Nishimura K, et al. Bacillus Calmette-Guerin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. Eur Urol. 2000;38(6):701–4;discussion 5.Google Scholar
  42. 42.
    Nishino Y, Yamamoto N, Komeda H, Takahashi Y, Deguchi T. Bacillus Calmette-Guerin instillation treatment for carcinoma in situ of the upper urinary tract. BJU Int. 2000;85(7):799–801.CrossRefPubMedGoogle Scholar
  43. 43.
    Wang AJ, Goldsmith ZG, Neisius A, Astroza GM, Oredein-McCoy O, Iqbal MW, et al. Increasing dwell time of mitomycin C in the upper tract with a reverse thermosensitive polymer. J Endourol Endourol Soc. 2013;27(3):288–93.CrossRefGoogle Scholar
  44. 44.
    Kohler R. Investigations on backflow in retrograde pyelography; a roentgenological and clinical study. Acta Radiol. 1953;39(99):1–92.PubMedGoogle Scholar
  45. 45.
    Auge BK, Pietrow PK, Lallas CD, Raj GV, Santa-Cruz RW, Preminger GM. Ureteral access sheath provides protection against elevated renal pressures during routine flexible ureteroscopic stone manipulation. J Endourol Endourol Soc. 2004;18(1):33–6.CrossRefGoogle Scholar
  46. 46.
    Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv Drug Deliv Rev. 2008;60(15):1627–37.CrossRefPubMedGoogle Scholar
  47. 47.
    Boix-Garriga E, Acedo P, Casado A, Villanueva A, Stockert JC, Canete M, et al. Poly(D, L-lactide-co-glycolide) nanoparticles as delivery agents for photodynamic therapy: enhancing singlet oxygen release and phototoxicity by surface PEG coating. Nanotechnology. 2015;26(36):365104.CrossRefPubMedGoogle Scholar
  48. 48.
    Khaled YS, Wright K, Melcher A, Jayne D. Anti-cancer effects of oncolytic viral therapy combined with photodynamic therapy in human pancreatic cancer cell lines. Lancet. 2015;385(Suppl 1):S56.CrossRefPubMedGoogle Scholar
  49. 49.
    Choi KH, Chung CW, Kim CH, Kim do H, Jeong YI, Kang DH. Effect of 5-aminolevulinic acid-encapsulate liposomes on photodynamic therapy in human cholangiocarcinoma cells. J Nanosci Nanotechnol. 2014;14(8):5628–32.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Saman Moazami
    • 1
  • Mark P. Schoenberg
    • 1
  • Joshua M. Stern
    • 1
  1. 1.Department of UrologyMontefiore Medical Center/Albert Einstein College of MedicineBronxUSA

Personalised recommendations